Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen

Chinese Medical Journal

Volumn 124, Issue 15, 2011, Pages 2335-2339

  Gao, Wan Li ^a   Zhang, Lu Ping ^a   Feng, Li Min ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Endometrium; Hysteroscopy; Postmenopausal breast cancer; Tamoxifen; Ultrasonography

Indexed keywords

TAMOXIFEN;

ABDOMINAL HYSTERECTOMY; ADENOMYOMATOSIS; ADULT; AGED; ARTICLE; BREAST ATROPHY; BREAST CANCER; BREAST HYPERPLASIA; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG RESPONSE; ENDOMETRIUM BIOPSY; ENDOMETRIUM POLYP; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; INCIDENTAL FINDING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYSTEROSCOPY; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN;

EID: 79961090426     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.15.016     Document Type: Article

References (26)

1. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004; 94: 256-266.
2. Garuti G, Cellani F, Centinaio G, Sita G, Nalli G, Luerti M. Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer. Gynecol Oncol 2006; 101: 269-273.
3. Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 2005; 97: 375-384.
4. Singh MN, Stringfellow HF, Paraskevaidis E, Martin-Hirsch PL, Martin FL. Tamoxifen: important considerations of a multi-functional compound with organ-specific properties. Cancer Treat Rev 2007; 33: 91-100.
5. Rieck GC, Freites ON, Williams S. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol 2005; 25: 39-41.
6. Gumus II, Keskin EA, Kilic E, Aker A, Kafali H, Turhan NO. Diagnostic value of hysteroscopy and hysterosonography in endometrial abnormalities in asymptomatic postmenopausal women. Arch Gynecol Obstet 2008; 278: 241-244.
7. Garuti G, Cellani F, Centinaio G, Sita G, Nalli G, Luerti M. Baseline endometrial assessment before tamoxifen for breast cancer in asymptomatic menopausal women. Gynecol Oncol 2005; 98: 63-67.
8. Garuti G, Grossi F, Centinaio G, Sita G, Nalli G, Luerti M. Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer. Eur J Obstet Gynecol Reprod Biol 2007; 132: 101-106.
9. Menada MV, Papadia A, Lorenzi P, Costantini S, Bertelli GF, Ragni N. Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. Eur J Gynaecol Oncol 2004; 25: 321-323.
10. Valenzano Menada M, Costantini S, Moioli M, Bogliolo S, Papadia A, Ferrero S, Dugnani MC. Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. Breast 2008; 17: 631-636.
11. Fishman M, Boda M, Sheiner E, Rotmensch J, Abramowicz J. Changes in the sonographic appearance of the uterus after discontinuation of tamoxifen therapy. J Ultrasound Med 2006; 25: 469-473.
12. Deckardt R, Lueken RP, Gallinat A, Möller CP, Busche D, Nugent W, et al. Comparison of transvaginal ultrasound, hysteroscopy, and dilatation and curettage in the diagnosis of abnormal vaginal bleeding and intrauterine pathology in perimenopausal and postmenopausal women. J Am Assoc Gynecol Laparosc 2002; 9: 277-282.
13. Gerber B, Krause A, Müller H, Reimer T, Külz T, Makovitzky J, et al. Effects of adjuvant TAM on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000; 18: 3464-3470.
14. Mbatsogo BA, Le Bouëdec G, Michy T, Bourdel N, Fouilloux G, Dauplat J. et al. Endometrial cancers arising in polyps associated with TAM use. Gynecol Obstet Fertil 2005; 33: 975-979.
15. Giorda G, Crivellari D, Veronesi A, Perin T, Campagnutta E, Carbone A, et al. Comparison of ultrasonography, hysteroscopy, and biopsy in the diagnosis of endometrial lesions in postmenopausal tomoxifen-treated patients. Acta Obstet Gynecol Scand 2002; 81: 975-980.
16. Fung MF, Reid A, Faught W, Le T, Chenier C, Verma S, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 2003; 91: 154-159.
17. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006; 107: 1475-1478.
18. Yela DA, Ravacci SH, Monteiro IM, Pereira KC, Gabiatti JR. Comparative study of transvaginal sonography and outpatient hysteroscopy for detection of pathologic endometrial lesions in postmenopausal women. Rev Assoc Med Bras 2009; 55: 553-556.
19. Ribeiro CT, Rosa-E-Silva JC, Silva-de-Sá MF, Rosa-E-Silva AC, Poli Neto OB, Candido Dos Reis FJ, et al. Hysteroscopy as a standard procedure for assessing endometrial lesions among postmenopausal women. Sao Paulo Med J 2007; 125: 338-342.
20. Zhu HL, Liang XD, Wang JL, Cui H, Wei LH. Hysteroscopy and directed biopsy in the diagnosis of endometrial carcinoma. Chin Med J 2010; 123: 3524-3528.
21. Angioni S, Loddo A, Milano F, Piras B, Minerba L, Melis GB. Detectionod benign intracavitary lesions in postmenopausal women with abnormal uterine bleeding: a prospective comparative study on outpatient hysteroscopy and blind biopsy. J Minim Invasive Gynecol 2008; 15: 87-91.
22. Svirsky R, Smorgick N, Rozowski U, Sagiv R, Feingold M, Halperin R, et al. Can we rely on blind endometrial biopsy for detection of focal intrauterine pathology? Am J Obstet Gynecol 2008; 199: 115e1-115e3.
23. Garuti G, Cellani F, Colonnelli M, Garzia D, Gonfiantini C, Luerti M. Hysteroscopically targeted biopsies compared with blind samplings in endometrial assessment of menopausal women taking tamoxifen for breast cancer. J Am Assoc Gynecol Laparosc 2004; 11: 62-67.
24. Markovitch O, Tepper R, Fishman A, Aviram R, Cohen I. Long-term follow-up of postmenopausal breast cancer patients following discontinuation of tamoxifen therapy. Maturitas 2008; 59: 387-393.
25. Garuti G, Cellani F, Centinaio G, Montanari G, Nalli G, Luerti M. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. Gynecol Oncol 2006; 103: 599-603.
26. Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 2002; 101: 58-63.